伴血栓性微血管病的严重高血压:需针对发病机制的治疗
本综述探讨伴血栓性微血管病(TMA)的严重高血压的诊治挑战。补体介导的TMA患者中相当比例表现为严重或恶性高血压,而血压极度升高本身也可诱导TMA样血管病变。在补体基因检测结果(需数周至数月)出来前,需快速排查继发性高血压和继发性TMA,并依据临床和病理数据尽早启动补体阻断剂。
要点
- 严重高血压伴TMA需快速排除继发性高血压与继发性TMA,二者需针对病因治疗。
- 补体介导TMA与高血压诱导的TMA鉴别困难,基因检测耗时数周至数月。
- 在基因结果前,临床与病理数据可支持补体介导TMA诊断并尽早启用补体阻断剂。
核心结论
- 补体介导的TMA与严重高血压关系密切,需在基因检测结果前依据临床和病理数据尽早识别并启动补体阻断剂治疗。
研究设计与样本
- 本文为综述,分析伴TMA的严重高血压的临床与组织学数据,未报告系统检索范围或样本量。
主要发现
- 近期研究显示,高比例的补体介导TMA患者表现为严重和恶性高血压。
- 血压极度升高本身可诱导血栓性微血管病的血管病变。
- 继发性高血压中血液学特征罕见,继发性TMA需治疗特定病因。
关键数值与推荐
- 补体介导TMA与原发性高血压的确定性鉴别需补体基因检测,结果通常需数周至数月。
- 在基因检测结果前,支持补体介导TMA诊断的临床和组织学数据可促使快速启动补体阻断剂。
临床怎么用
- 对严重高血压伴TMA患者,应快速排查继发性高血压和继发性TMA。
- 在补体基因检测结果回报前,可依据临床和病理数据尽早启动补体阻断剂。
局限性
- 该病在发病机制、诊断和治疗方面存在众多未满足的空白,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant hypertension with acute kidney injury or acute kidney disease is a life-threatening condition requiring urgent antihypertensive treatment and which carries a serious risk of kidney function loss. The presence of thrombotic microangiopathy (microangiopathic hemolytic anemia and thrombocytopenia) further challenges the diagnosis and treatment of these patients. As shown by recent studies, a high proportion of patients with complement-mediated thrombotic microangiopathy present with severe and malignant hypertension; however, extreme elevation of blood pressure by itself can induce vascular lesions of thrombotic microangiopathy. To resolve this conundrum, it is essential to rapidly investigate and exclude forms of secondary hypertension (in which hematologic features are rare) and secondary thrombotic microangiopathies, both of which require treatment of the specific underlying etiology. Definitive differentiation of essential hypertension and complement-mediated thrombotic microangiopathy requires complement genetic testing, the results of which usually take weeks to months. In this review, we analyze the clinical and histologic data that would support the diagnosis of complement-mediated thrombotic microangiopathy before the results of genetic tests, prompting the rapid initiation of complement blockers. However, there are numerous unmet gaps in the pathogenesis, diagnosis, and treatment of this disorder that require further research.
引用
- Praga M, Caravaca-Fontán F, Cavero T, et al. Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments. Kidney Int. 2025. PMID: 41274409. doi:10.1016/j.kint.2025.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。